Rxivist logo

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2

By Catherine Z Chen, Paul Shinn, Zina Itkin, Richard Eastman, Robert Bostwick, Lynn Rasmussen, Ruili Huang, Min Shen, Xin Hu, Kelli M Wilson, Brianna Brooks, Hui Guo, Tongan Zhao, Carleen Klumpp-Thomas, Anton Simeonov, Samuel G. Michael, Donald C. Lo, Matthew D. Hall, Wei Zheng

Posted 18 Aug 2020
bioRxiv DOI: 10.1101/2020.08.18.255877

Drug repurposing is a rapid approach to identifying therapeutics for the treatment of emerging infectious diseases such as COVID-19. To address the urgent need for treatment options, we carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products. Three hundred and nineteen compounds with anti-SARS-CoV-2 activities were identified and confirmed, including 91 approved drug and 49 investigational drugs. Among these confirmed compounds, the anti-SARS-CoV-2 activities of 230 compounds, including 38 approved drugs, have not been previously reported. Chlorprothixene, methotrimeprazine, and piperacetazine were the three most potent FDA approved drugs with anti-SARS-CoV-2 activities. These three compounds have not been previously reported to have anti-SARS-CoV-2 activities, although their antiviral activities against SARS-CoV and Ebola virus have been reported. These results demonstrate that this comprehensive data set of drug repurposing screen for SARS-CoV-2 is useful for drug repurposing efforts including design of new drug combinations for clinical trials. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 1,236 times
  • Download rankings, all-time:
    • Site-wide: 27,689
    • In microbiology: 1,557
  • Year to date:
    • Site-wide: 100,242
  • Since beginning of last month:
    • Site-wide: 160,252

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

News